C-reactive protein predicts death in patients with non-ischemic cardiomyopathy

Cardiology

Volumn 104, Issue 4, 2005, Pages 196-201

  Ronnow, Brianna S ^a   Reyna, Sandra P ^a   Muhlestein, Joseph B ^a,b   Horne, Benjamin D ^a   Allen Maycock, Chloe A ^a   Bair, Tami L ^a   Carlquist, John F ^a,b   Kfoury, Abdallah G ^a   Anderson, Jeffrey L ^a,b   Renlund, Dale G ^a,b,c  

^a LDS HOSPITAL   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Heart failure; Inflammation; Left ventricular dysfunction

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; C REACTIVE PROTEIN; HYPOCHOLESTEROLEMIC AGENT;

ADULT; AGED; ARTICLE; CARDIOMYOPATHY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; COVARIANCE; FATALITY; FEMALE; HEART CATHETERIZATION; HEART DEATH; HEART LEFT VENTRICLE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTION; PRIORITY JOURNAL;

AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOMYOPATHIES; CORONARY ARTERIOSCLEROSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL ISCHEMIA; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; STROKE VOLUME; SURVIVAL ANALYSIS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 26044452370     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000088138     Document Type: Article

References (33)

1. American Heart Association: Heart Disease and Stroke Statistics - 2004 Update. Dallas, Am Heart Assoc, 2003.
2. Cleland JG, Dargie HJ, Ford I: Mortality in heart failure. Clinical variables of prognostic value. Br Heart J 1987;58:572-582.
3. Lacoste L, Lam JY, Hung J, Letchacovski G, Solymoss CB, Waters D: Correction of the increased thrombogenic potential with cholesterol reduction. Circulation 1995;92:3172-3177.
4. Albert MA, Danielson E, Rifai N, Ridker PM, PRINCE Investigators: Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001;286:64-70.
5. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, Gotto AM Jr, Air Force/ Texas Coronary Atherosclerosis Prevention Study Investigators: Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001;344:1959-1965.
6. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E: Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999;100:230-235.
7. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Move LA, Goldman S, Flaker GC, Braunwald E: Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998;98:839-844.
8. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-979.
9. Ridker PM, Hennekens CH, Buring JE, Rifai N: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-843.
10. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH: Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 1998;97:425-428.
11. Mendall MA, Strachan DP, Butland BK, Ballam L, Morris J, Sweetnam PM, Elwood PC: C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men. Eur Heart J 2000;21:1584-1590.
12. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, Gallimore JR, Pepys MB: Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 2000;321:199-204.
13. Kuller LH, Tracy RP, Shaten J, Meilahn EN: Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol 1996;144:537-547.
14. Horne BD, Muhlestein JB, Carlquist JF, Bair TL, Madsen TE, Hart NI, Anderson JL: Statin therapy, lipid levels, C-reactive protein and the survival of patients with angiographically severe coronary artery disease. J Am Coll Cardiol 2000;36:1774-1780.
15. Chew DP, Bhatt DL, Robbins MA, Penn MS, Schneider JP, Lauer MS, Topol EJ, Ellis SG: Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention. Circulation 2001;104:992-997.
16. Muhlestein JB, Horne BD, Carlquist JF, Madsen TE, Bair TL, Pearson RR, Anderson JL: Cytomegalovirus seropositivity and C-reactive protein have independent and combined predictive value for mortality in patients with angiographically demonstrated coronary artery disease. Circulation 2000;102:1917-1923.
17. Tousoulis D, Homaei H, Ahmed N, Asimakopoulos G, Zouridakis E, Toutouzas P, Davies GJ: Increased plasma adhesion molecule levels in patients with heart failure who have ischemic heart disease and dilated cardiomyopathy. Am Heart J 2001;141:277-280.
18. Kaneko K, Kanda T, Yamauchi Y, Hasegawa A, Iwasaki T, Arai M, Suzuki T, Kobayashi I, Nagai R: C-reactive protein in dilated cardiomyopathy. Cardiology 1999;91:215-219.
19. Alonso-Martinez JL, Llorente-Diez B, Echegaray-Agara M, Olaz-Preciado F, Urbieta-Echezarreta M, Gonzalez-Arencibia C: C-reactive protein as a predictor of improvement and readmission in heart failure. Eur J Heart Fail 2002;4:331-336.
20. Sato Y, Takatsu Y, Kataoka K, Yamada T, Taniguchi R, Sasayama S, Matsumori A: Serial circulating concentrations of C-reactive protein, interleukin (IL)-4, and IL-6 in patients with acute left heart decompensation. Clin Cardiol 1999;22:811-813.
21. Mann DL, Young JB: Basic mechanisms in congestive heart failure: recognizing the role of proinflammatory cytokines. Chest 1994;105:897-904.
22. Berton G, Cordiano R, Palmieri R, Pianca S, Pagliara V, Palatini P: C-reactive protein in acute myocardial infarction: association with heart failure. Am Heart J 2003;145:1094-1101.
23. Vasan RS, Sullivan LM, Roubenoff R, Dinarello CA, Harris T, Benjamin EJ, Sawyer DB, Levy D, Wilson PW, D'Agostino RB: Framingham Heart Study. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction. Circulation 2003;107:1486-1491.
24. Yin WH, Chen JW, Jen HL, Chiang MC, Huang WP, Feng AN, Young MS, Lin SJ: Independent prognostic value of elevated high-sensitivity C-reactive protein in chronic heart failure. Am Heart J 2004;147:931-938.
25. Werdan K: The activated immune system in congestive heart failure - From dropsy to the cytokine paradigm. J Intern Med 1998;243:87-92.
26. Hasper D, Hummel M, Kleber FX, Reindl I, Volk HD: Systemic inflammation in patients with heart failure. Eur Heart J 1998;19:761-765.
27. Levine B, Kalman J, Mayer L, Fillit HM, Packer M: Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Eng J Med 1990;323:236-241.
28. Matsumori A, Yamada T, Suzuki H, Matoba Y, Sasayama S: Increased circulating cytokines in patients with myocarditis and cardiomyopathy. Br Heart J 1994;72:561-566.
29. Taylor GS, Muhlestein JB, Wagner GS, Bair TL, Li P, Anderson JL: Implementation of a computerized cardiovascular information system in a private hospital setting. Am Heart J 1998;136:792-803.
30. Anonymous: Myocardial infarction and mortality in the coronary artery surgery study (CASS) randomized trial. N Engl J Med 1984;310:750-758.
31. Clarke JL, Anderson JL, Carlquist JF, Roberts RF, Horne BD, Bair TL, Kolek MJ, Mower CP, Crane AM, Roberts WL, Muhlestein JB, Intermountain Heart Collaborative (IHC) Study Group: Do differing CRP assay methods impact cardiovascular risk assessment? Am J Cardiol 2005;95:155-158.
32. Buffon A, Liuzzo G, Biasucci LM, Pasqualetti P, Ramazzotti V, Rebuzzi AG, Crea F, Maseri A: Preprocedural serum levels of C-reactive protein predict early complications and late restensosis after coronary angioplasty. J Am Coll Cardiol 1999;34:1512-1521.
33. Morrow DA, Rifai N, Antman EM, Weiner DL, McCabe CH, Cannon CP, Braunwald E: C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. J Am Coll Cardiol 1998;31:1460-1465.